CPT1A and chronic kidney disease: Genetically engineered macrophages overexpressing carnitine palmitoyltransferase 1a (CPT1a) exhibit augmented phagocytic activity by facilitating fatty acid oxidation and extracellular matrix clearance, suppressing pro-fibrotic cytokine release in CKD (138, 139).